Close Menu

NEW YORK – Transplant diagnostics company CareDx has released a new version of its signature organ transplant diagnostic AlloSure, which can now detect if patients are showing signs of borderline, subclinical T-cell mediated rejection (TCMR).

AlloSure 3.0, the latest iteration of the company's donor-derived cell-free DNA (dd-cfDNA) test, is specifically meant to enable doctors to detect the earliest and most "ambiguous" signs of rejection that are often undetectable through other means," according to CareDx Chief Commercial Officer Sasha King.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.